PT - JOURNAL ARTICLE AU - Yokoyama, Hiroki AU - Araki, Shin-ichi AU - Yamazaki, Katsuya AU - Kawai, Koichi AU - Shirabe, Shin-Ichiro AU - Oishi, Mariko AU - Kanatsuka, Azuma AU - Yagi, Noriharu AU - Kabata, Daijiro AU - Shintani, Ayumi AU - Maegawa, Hiroshi ED - , TI - Trends in glycemic control in patients with insulin therapy compared with non-insulin or no drugs in type 2 diabetes in Japan: a long-term view of real-world treatment between 2002 and 2018 (JDDM 66) AID - 10.1136/bmjdrc-2021-002727 DP - 2022 May 01 TA - BMJ Open Diabetes Research & Care PG - e002727 VI - 10 IP - 3 4099 - http://drc.bmj.com/content/10/3/e002727.short 4100 - http://drc.bmj.com/content/10/3/e002727.full SO - BMJ Open Diab Res Care2022 May 01; 10 AB - Introduction We investigated trends in the proportion of diabetes treatment and glycemic control, which may be altered by recent advances in insulin and non-insulin drugs, in Japanese patients with type 2 diabetes.Research design and methods A serial cross-sectional study was performed using a multicenter large-population database from the Japan Diabetes Clinical Data Management study group. Patients with type 2 diabetes who attended clinics belonging to the study group between 2002 and 2018 were included to examine trends in glycated hemoglobin A1c (HbA1c) by treatment group using multivariable non-linear regression model.Results The proportion of patients with insulin only decreased from 15.0% to 3.6%, patients with insulin+non-insulin drugs increased from 8.1% to 15.1%, patients with non-insulin drugs increased from 50.8% to 67.0%, and those with no drugs decreased from 26.1% to 14.4% from 2002 to 2018, respectively. The HbA1c levels of each group, except for no drugs, continued to decrease until 2014 (unadjusted mean HbA1c (%) from 2002 to 2014: from 7.89 to 7.45 for insulin only, from 8.09 to 7.63 for insulin+non-insulin, and from 7.51 to 6.98 for non-insulin) and remained unchanged thereafter. Among insulin-treated patients, use of human insulin decreased, use of long-acting analog insulin increased, and concomitant use of non-insulin drugs increased (from 35.1% in 2002 to 80.9% in 2018), which included increased use of dipeptidyl peptidase 4 inhibitors, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide 1 receptor agonists, and the persistently high use of metformin.Conclusions During the past two decades, combined use of insulin and non-insulin drugs increased and glycemic control improved and leveled off after 2014 in Japanese patients with type 2 diabetes. Further studies of the trend in association with age and factors related to metabolic syndrome are necessary to investigate strategies aiming at personalized medicine in diabetes care.Data are available upon reasonable request.